Fig. 3

The efficacy of MP in early ACLF (those without ascites, without encephalopathy) and advanced stage ACLF. a The survival analysis of patients with ACLF in different four groups. b The survival analysis of patients with ACLF between methylprednisolone group and control group in early ACLF (those without ascites, without encephalopathy) during 30 days, 60 days, and 90 days. c The survival analysis of patients with ACLF between methylprednisolone group and control group in advanced ACLF during 30 days, 60 days, and 90 days. d The survival analysis of patients with ACLF between methylprednisolone group and control group in early ACLF (those without ascites, without encephalopathy) during 120 days, 150 days, and 180 days. e The survival analysis of patients with ACLF between methylprednisolone group and control group in advanced ACLF during 30 days, 60 days, and 90 days